Knowledge of the blast phenotype in myelodysplastic syndromes (MDS) would be valuable, as in other malignancies, but remains sparse. This is mainly because MDS blasts are a minor population in clinical samples, making analysis difficult. Thus, for this blast phenotype study, we prepared blast-rich specimens (using a new density-centrifugation reagent for harvesting blasts) from blood 
Introduction
Myelodysplastic syndromes (MDS) is a malignant disorder of hematopoietic progenitors in which the bone marrow (BM) is composed of clonal hematopoietic cells showing various degrees of differentiation in each case. [1] [2] [3] The French-American-British (FAB) cooperative group proposed five subgroups of MDS based mainly on the percentage of blasts in the BM and peripheral blood (PB),
i.e., refractory anemia (RA), RA with ringed sideroblasts (RARS), chronic myelomonocytic leukemia (CMML), RA with excess blasts (RAEB) and RAEB in transformation (RAEB-t). 4 and the number of antibodies used was small. Phenotypic data for MDS blasts would be useful for the following reasons. First, the phenotype of MDS blasts would help in the development and application of therapeutic agents for targeting cell surface antigens, like the anti-CD33
calichaemicin conjugate and inhibitors of receptor tyrosine kinase (RTK) for de novo AML. 13, 14 Second, knowledge of the blast phenotype could help to predict the outcome of patients. Third, blast phenotype data could be used to subclassify MDS and distinguish between MDS and de novo AML.
To date the latter has been done arbitrarily on the basis of the percentage of blasts in the BM and/or PB, which is not biologically relevant.
One of the present authors developed a method, using metrizamide density-centrifugation, for harvesting blasts of high purity and high recovery from PB and BM of MDS patients. 15 Based on this method, a stable density-centrifugation reagent for reproducibly harvesting viable blasts was developed. 16 This is a novel reagent not containing Ficoll-Hypaque, Percoll or albumin. Regarding MDS blasts, which often exist as a minor cell population in samples, there had been no reliable data (such as their pattern on the CD45 versus SSC display of FCM) for gating of blasts by FCM.
Therefore, in this study, we used that new density-centrifugation reagent to obtain blast-rich specimens from patients with MDS and AL-MDS, which allowed reliable blast gating to determine the phenotype of enriched blast cells (EBCs) in most of the patients at diagnosis (n = 116). We also analyzed the EBC phenotype after disease progression in some patients. This is the first report to present the detailed phenotypic features of MDS blasts and their clinical significance.
Materials and methods

Subjects
MDS and AL-MDS patients who had been diagnosed and treated at the seven participating institutions during 1998-2000 were the subjects of this study. Patients who had previously undergone cytotoxic chemotherapy and those with secondary MDS were excluded. Disease
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From diagnoses were made according to the FAB criteria. 4, 17 Cytogenetic analyses were performed using standard G-banding with trypsin-Giemsa staining. Karyotypes were interpreted using the International System for Cytogenetic Nomenclature criteria. 18 The IPSS of each MDS patient was determined according to the definition reported by Greenberg et al. 8 Cell preparation
Heparinized aspirated BM cells were obtained for clinical diagnosis, and soon after the diagnosis heparinized PB was obtained from the patients. PB samples which contained at least 0.25% blasts were used. The volume of aspirated BM cells used for harvesting blasts was at least 4 ml in RA and RARS cases and at least 1.5 ml in cases with other disease subtypes. Heparinized aspirated BM cells were also obtained from normal volunteers. Informed consent was obtained from all subjects.
A density-gradient centrifugation reagent for harvesting blasts (Blastretriever [BR]) was kindly provided by Japan Immunoresearch Laboratories Co. (Takasaki, Japan). Blast harvesting from the heparinized samples was performed according to the manufacturer's instructions. That is, up to 2.5 ml of sample (unmanipulated PB or BM cells diluted three-fold with RPMI 1640 medium) was layered onto 2.5 ml of the BR solution in a glass tube (inner diameter: 14 mm) and spun at 550 x g for 10 minutes at room temperature. The low-density cells were taken from the BR interface, washed with RPMI 1640 medium containing 10% fetal calf serum, and used for FCM and cytospin preparations. The cell differential was determined from Wright-Giemsa-stained cytospin preparations. In some experiments, cell viability was determined by trypan blue dye exclusion, and the cell count was determined with a hemocytometer.
FCM and cytochemistry
Immunophenotyping was performed by three-color FCM, in which EBCs and other cell populations were gated by a CD45 gating method. 19, 20 In brief, the cells were stained with anti-CD45 antibody were directed to CD3, CD5, CD8, CD15, CD16, CD19, CD25, CD34, HLA-DR (FITC-conjugated; Becton Dickinson), CD4, CD11b, CD13, CD14, CD34 (PE-conjugated; Becton Dickinson), CD2, CD7, CD38 (FITC-conjugated; Pharmingen, San Diego, CA), CD20, CD33, CD56 (PE-conjugated; Pharmingen), CD10, CD117 and glycophorin A (PE-conjugated; Coulter-Immunotech, Hialeah, FL).
Single-labeled cells were used to compensate for fluorescence emission overlap of each fluorochrome into inappropriate channels. Isotype-matched negative controls were used in all assays. At least 10,000 events were acquired for most samples. Expression of each antigen was regarded as positive when at least 20% of gated cells were more fluorescent than the negative control. Analysis was performed on a FACScan (Becton Dickinson).
Cytospin preparations were subjected to cytochemical stains (myeloperoxidase [MPO] and nonspecific esterase [alpha-naphthyl butyrate esterase]). 15, 16 The results of cytochemistry were judged to be positive when at least 3% of blasts were positive for each stain.
Statistical analyses
Differences between two groups of data of continuous variables were analyzed by Student's t-test.
Differences in categorical variables were evaluated using the chi-square test. The duration of overall survival (OS) was calculated from the time of diagnosis (almost identical to the date of the blast phenotyping) until death. The duration of transformation-free survival (TFS) was calculated from the time of diagnosis until the date of transformation to acute leukemia. Patients dying from any cause without developing acute leukemia were treated as censored data regarding the date of death in the TFS analysis. Patients who underwent SCT or who were lost to follow-up were also censored regarding the date of SCT or the last follow-up in both the OS and TFS analyses. Survival curves were obtained by the Kaplan-Meier method and compared by the log-rank test or, when applicable, 
Results
Validity of the use of BR density centrifugation Figure 1 presents an example of blast-enrichment by BR density centrifugation. When PB containing 1.5% blasts ( Figure 1A ) was obtained from an MDS patient and subjected to BR density centrifugation, nucleated cells were separated into two fractions, i.e., the BR interface and BR precipitate. While erythrocytes were exclusively in the BR precipitate, blasts were recovered in the BR interface with high purity ( Figure 1B ) but were negligible in the BR precipitate ( Figure 1C ).
Reagents for mononuclear cell isolation, such as Ficoll-Paque, could not sufficiently enrich blasts from the same PB sample ( Figure 1D ). When aspirated BM cells from normal volunteers (n = 5) were subjected to BR density centrifugation and analyzed by FCM, both myeloblasts Figure 1F ). These cell populations were not detected on the same display for cells in the BR precipitate (data not shown). We then confirmed that the results of immunophenotyping and cytochemistry of blasts did not differ between unprocessed blasts and blasts obtained by BR density centrifugation for all the examined samples (n = 64) which had been obtained from acute lymphocytic leukemia, AML and RAEB-t cases (representative immunophenotyping of blasts in unprocessed samples and blasts separated by BR density centri fugation from the same samples are shown in Figure 1 (G-J)). The recovery of blasts after BR density centrifugation (the number of blasts in the BR interface divided by the number of blasts in the unseparated sample) was
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Blast-enrichment by BR centrifugation from 143 samples Cell samples (n = 143) from patients with MDS and AL-MDS were subjected to BR density centrifugation, and the blast fraction (the BR interface) was collected for subsequent analyses. Figure 2 shows the correlation between the percentage of blasts in these samples before and after the centrifugation. Blast-enrichment was achieved for both the aspirated BM cells and PB, and was more efficient in the latter. The smallest percentage of blasts in these 143 samples before centrifugation was 0.25%, which was observed in three PB samples. The percentages of blasts after the BR density centrifugation of these three samples were 44%, 46% and 96%. Figure 3B , and the cardinal data of the antigen profiles for four gated cell populations are shown in Table 1 . The cells in R1 in this case were confirmed to be blasts with a myeloid phenotype on the basis of the following findings. (1) Expression of CD34 is a definitive indicator of blasts, as is the expression of HLA-DR without CD11b on moderately CD45 + cells. 21 The cells in R1 in this case met both of these criteria. Similar to these examples, the reliability of flow cytometric gating of blasts was carefully checked for all 143 samples, and six samples were excluded from the subsequent analyses (three samples due to insufficient cell number and three samples due to inaccurate gating of the blasts).
Thus, data for 137 samples from 116 cases (both PB and BM samples for 21 cases) were analyzed. Table 2 shows the characteristics of these 116 cases. Because a larger volume of aspirated BM cells was needed for harvesting blasts from RA and RARS cases, the number of these cases was relatively small compared with the other disease subtypes.
Immunophenotyping and cytochemistry of EBCs from 116 cases
The data for EBCs from 116 cases are summarized in Tables 3-4 . B-cell precursors, which can be detected in normal BM samples after BR density centrifugation, were detected in three cases (two RA and one RAEB cases) among the subjects whose BM cells were analyzed (n = 79). For these three cases, the data of gated blasts other than B-cell precursors are presented in Tables 3-4 . The data for PB and BM samples from the same subjects (n = 21) did not differ. We also show the immunophenotype of de novo AML blasts prepared by BR density centrifugation for comparison ( CD117, which is expressed on a subset of hematopoietic progenitors and mast cells in normal hematopoiesis, was expressed in 73/114 cases (64%). MPO was negative in 63/108 cases (58%).
The high prevalence of CD34 + cases and MPO -cases in MDS differs from the data of de novo AML (see discussion). During normal neutrophil maturation, CD15 and CD11b begin to appear on promyelocytes and myelocytes, respectively, and continue their expression to mature neutrophils. 23 These antigens were expressed in 73/114 cases (64%) and 53/111 cases (48%), respectively. Such asynchronous expression of antigens, i.e., expression of both stem cell antigens and maturation antigens, is well known in de novo AML, as shown in Table 5 and reported by others.
22,24 Table 4 shows the expression data for lymphoid-lineage-associated antigens. Among the T-cell associated antigens, no cases were CD3 + and/or CD8 + , and three cases were CD2 + or CD5 + .
Compared with these antigens, CD4 and CD7 are less restricted to lymphoid cells in normal hematopoiesis, i.e., the former is expressed on monocytes, and the latter is expressed on a fraction of CD34 + myeloid progenitors and proposed as a marker of immaturity in myeloid cells (see Discussion and CD117 differed significantly among them (Table 6 ), while the other data presented in Tables 3   and 4 did not. Markers for immaturity of myeloid cells (CD7 and CD117) were more prevalent in high-risk MDS and AL-MDS, whereas markers for maturation of myeloid cells (CD10 and CD15)
were more prevalent in low-risk MDS. In particular, none of 23 low-risk cases were CD7 + , and almost all low-risk MDS cases (21/22 cases) were CD15 + . We then investigated whether the difference in immunophenotype between MDS subtypes occurs during disease progression of individual cases. For this purpose we assumed that, among the four antigens presented in Table 6 , CD7 is a target marker. This assumption was based on the following reasons.
(1) During several years of follow-up, transformation from low-risk MDS to high-risk MDS or AL-MDS occurs at only a low frequency, while transformation from high-risk MDS to AL-MDS is more common. 8 (2) Among the four antigens, the percentage of CD7 + cases alone differed between RAEB, RAEB-t and AL-MDS (3 1%, 52% and 52%, respectively; P = .0466 for RAEB versus RAEB-t and AL-MDS).
Further, the percentage of EBCs positive for CD7 (mean of data from the positive cases) was highest in AL-MDS (RAEB 38%, RAEB-t 39% and AL-MDS 56%). We were able to examine the immunophenotype after disease progression in eight of the 116 cases ( 
Prognostic value of EBC phenotype in MDS
The IPSS is a well-validated prognostic index for MDS. 8 The IPSS is composed of three parameters,
i.e., the percentage of BM blasts, degree of cytopenia and karyotype. Although the data for these parameters change with time in MDS, the IPSS determined by the data at initial evaluation is strongly associated with the prognosis. Hence, we examined the prognostic value of the phenotype of EBCs at the initial evaluation in our MDS cases. At the time of survival analysis, 52 of the 95 MDS patients had died. The median follow-up for patients alive at the time of analysis was 20 months.
The age, IPSS and all variables presented in Tables 3 and 4 were analyzed for the MDS patients. AL-MDS patients were excluded from the analysis. The results of prognostic analyses for the cardinal variables are summarized in Table 8 . In univariate analysis, CD7-positivity ( 20% of EBCs expressing CD7) was significantly associated with a short OS (P = .0007, Figure 4A ) and TFS (P = .014). CD15 negativity (< 20% of EBCs expressing CD15) tended to be associated with a short OS (P = .092, Figure 4B ). When the MDS patients were divided into CD7 + CD15 show a poor prognosis. 26 Our MDS patients with EBCs of this phenotype (n = 6) did not show any significant survival disadvantage. We then analyzed the variables associated with the prognosis by multivariate analysis. CD7-positivity was an independent variable associated with a short OS and TFS, and "CD7 + and/or CD15 -" was an independent variable associated with a short OS (Table 8) .
Because CD7 + cases did not exist in low-risk MDS, we repeated the prognostic analysis for all of the above-mentioned variables in high-risk MDS patients. In the univariate analysis, CD7-positivity was associated with a short OS (P = .030, Figure 4D ) and TFS (P = .0073), but all other variables, including the IPSS, were not (P > .1).
We then evaluated the association between CD7 expression and IPSS. (Table 9 and Figure 4E ).
Discussion
Density gradient centrifugation using the BR reagent is suitable for enriching blasts from patients with myeloid malignancies and lymphoid malignancies 16 (and in Hyodo et al, manuscript in preparation). When this method was applied to normal BM cells, both myeloblasts and immature B cells were able to be enriched. In this study, we used this reagent to enrich MDS blasts and then 22 ) is common in MDS. In the meantime, expression of antigens restricted to lymphoid cells in normal hematopoiesis, i.e., CD2, CD3, CD5, CD8, CD19 and CD20, was very rare for the MDS EBCs. The exception is CD56, whose expression is observed only on NK cell-and a subset of T cell-lineages in normal subjects, was expressed on EBCs from 27% of our cases. This is consistent with the data for de novo AML as shown in Table 5 and reported by others.
32
The present data, i.e., 97% of the cases expressed CD34 and 58% of the cases were We showed that CD7-positivity, with or without consideration of the CD15 expression status, was an independent variable associated with a poor prognosis for MDS. Although the in vivo function of CD7 is largely unknown, it may be involved in T and NK cell activation and adhesion as well as production of granulocyte-macrophage colony-stimulating factor by myeloid precursors. [44] [45] [46] [47] It remains unknown whether these putative functions of CD7, blast immaturity itself or other factors explain the poor prognosis of CD7 + MDS cases. Regarding de novo AML, there is continued debate over whether CD7 expression is associated with a poor prognosis (reviewed in Ogata et al 20 ) .
However, in our recent study examining 256 de novo AML cases, we showed a strong association between the cytogenetic data and CD7 expression as described above, which explains why the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From prognostic value of CD7 expression has been contradictory in de novo AML. 20 Further, CD7 expression was associated with an extremely poor prognosis only when de novo AML patients with unfavorable cytogenetics were analyzed. 20 The finding that CD7 expression was associated with a poor prognosis in disease groups which per se have a poor prognosis, i.e., MDS and de novo AML with unfavorable cytogenetics, is interesting. The biologic background which explains this finding needs to be studied further.
In conclusion, this is the first report to clarify the detailed phenotypic features of MDS blasts and their clinical significance. We believe that the data presented here are clinically useful and important for understanding the pathophysiology of MDS. 
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